Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION
6.1.2 INCREASING GERIATRIC POPULATION
6.1.3 INCREASE IN PIPELINE PRODUCTS
6.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT AND PROCEDURES
6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 INCREASING RESEARCH AND DEVELOPMENT
6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD
6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
6.3.4 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD)
6.4 CHALLENGES
6.4.1 LIMITED ACCESS TO TREATMENT
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS
7 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE
7.1 OVERVIEW
7.2 DRY AMD
7.3 WET AMD
7.3.1 MEDICATIONS
7.3.2 ANTI-VEGF THERAPY
7.3.3 GENE THERAPY
7.3.4 SURGERY
8 NORTH AMERICA AGE- RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 SPECIALTY CLINICS
8.4 AMBULATORY SURGICAL CENTERS
8.5 HOME HEALTHCARE
8.6 OTHERS
9 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 RETAIL SALES
9.2.1 HOSPITAL PHARMACIES
9.2.2 RETAIL PHARMACIES
9.2.3 OTHERS
9.3 DIRECT TENDER
10 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION
10.1 NORTH AMERICA
10.1.1 U.S.
10.1.2 CANADA
10.1.3 MEXICO
11 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 NOVARTIS AG
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENT
13.1.5.1 AGREEMENT
13.2 GENENTECH, INC.
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENT
13.3 BAYER AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 ADVERUM BIOTECHNOLOGIES, INC.
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENT
13.5 ASTELLAS PHARMA INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENT
13.6 GRAYBUG VISION INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENT
13.7 GENSIGHT BIOLOGICS
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.7.4.1 EVENT
13.7.4.2 AWARD
13.8 IONIS PHARMACEUTICALS
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENT
13.8.4.1 EVENT
13.9 IVERIC BIO
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 JOHNSON &JOHNSON SERVICES, INC.
13.10.1 COMPANY SNAPSHOT
13.10.2 REVENUE ANALYSIS
13.10.3 PRODUCT PORTFOLIO
13.10.4 RECENT DEVELOPMENT
13.10.4.1 COLLABORATION
13.11 KODIAK SCIENCES INC.
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 MEIRAGTX LIMITED
13.12.1 COMPANY SNAPSHOT
13.12.2 PRODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENTS
13.12.3.1 EVENTS
13.12.3.2 AWARD
13.12.3.3 COLLABORATION
13.13 OCUGEN INC.
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENTS
13.13.3.1 INVESTMENT
13.13.3.2 CLINICAL TRIAL
13.14 PIXIUM VISION
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 PRODUCT PORTFOLIO
13.14.4 RECENT DEVELOPMENT
13.14.4.1 AWARD
13.15 REGENXBIO INC.
13.15.1 COMPANY SNAPSHOT
13.15.2 PRODUCT PORTFOLIO
13.15.3 RECENT DEVELOPMENTS
13.15.3.1 EVENT
13.15.3.2 COLLABORATION
13.15.3.3 CERTIFICATION
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 VARIOUS EXAMPLES OF OPHTHALMIC DEVICES ARE SUMMARIZED IN THE BELOW-GIVEN TABLE ACCORDING TO THEIR CLASSIFICATION
TABLE 2 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 U.S. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 26 U.S. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 U.S. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 U.S. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 30 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 CANADA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 CANADA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 CANADA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 CANADA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL,, 2020-2029 (USD MILLION)
TABLE 36 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 MEXICO WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 MEXICO MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 MEXICO AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 41 MEXICO RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRY AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET
FIGURE 16 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2021
FIGURE 17 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2021
FIGURE 21 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 22 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 24 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 25 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 26 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 28 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET : SNAPSHOT (2021)
FIGURE 29 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET : BY COUNTRY (2021)
FIGURE 30 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET : BY COUNTRY (2022 & 2029)
FIGURE 31 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET : BY COUNTRY (2021 & 2029)
FIGURE 32 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET : BY TYPE (2022-2029)
FIGURE 33 NORTH AMERICA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE MARKET: COMPANY SHARE 2021 (%)
